4'-Thio-2'-Deoxycytidine (TdCyd)
Advanced Solid Tumors
Phase 1Active
Key Facts
About Alchem Laboratories
Alchem Laboratories is a long-established, private biotech firm with a dual focus on infectious disease therapeutics and a robust contract development and manufacturing (CDMO) service for clinical-stage APIs. Its core capabilities include custom synthesis, assay development, and high-throughput screening (HTS), supported by leadership with deep experience in drug delivery and government contracting. While its public pipeline data shows activity in oncology and other areas, its stated mission centers on advancing antiviral and antibody treatments, positioning it at the intersection of internal R&D and external service provision.
View full company profileTherapeutic Areas
Other Advanced Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| NT219 | Purple Biotech | Phase 1/2 |
| INDP-101 | Indaptus Therapeutics | Phase 1 |
| NST-101 (estimated) | Novastage Pharmaceuticals | Phase 1/2 |
| Meta10-TILs | Leman Biotech | Phase 1 |
| PM14 | PharmaMar | Phase 1/2 |
| Ecubectedin (PM54) | PharmaMar | Phase 1 |
| M8891 | Merck KGaA | Phase 1/2 |
| P-002 | Panacea Biotec | Phase 1/2 |
| Undisclosed kinase inhibitor | Tyligand Bioscience | Phase 1 |
| TYK-001 | TYK Medicines | Phase 1/2 |
| PT-112 | SciClone Pharmaceuticals | Phase 1 |
| AP-202 | Advance Pharmaceutical | Phase 1/2 |